Solid Dosage
GEA supplies solutions for manufacturing inhalable and oral antiviral drugs ranging from blending, spray drying and particle engineering to continuous manufacturing.
Antiviral medications help the body to fight off harmful viruses such as influenza, chickenpox and the human immunodeficiency virus (HIV), to name a few. The drugs can ease symptoms and shorten the length of a viral infection. Antivirals also lower the risk of getting or spreading viruses that cause herpes and HIV. One approved antiviral treats the coronavirus that causes COVID-19.
Antiviral drugs are also preventive. They can protect you from getting viral infections or spreading a virus to others. They come in many formats, including tablets, intravenous solutions, liquids and inhaled powders.
For inhalable versions, GEA understands that homogeneity and stability are key factors. Our dry powder blending, spray drying and particle engineering capabilities ensure that the production of free-flowing, aerodynamic particles at the correct size is achievable at the scale you need.
And, with the ongoing development of oral anti-viral medications, particularly as a result of the COVID-19, pandemic, there is increased interest in the use of continuous manufacturing to accelerate process design and product optimization.
For example, the compact and fully integrated ConsiGma®4.0 platform has been designed to transfer powder into coated tablets in a shorter time frame. Plus, by combining Quality by Design (QbD) principles with Design of Experiments (DoE), it enables operators to explore the design space in a quick and easy way and expedite time-to-market.
Mostrar 4 de 26

Como integradores de sistemas, unimos nuestro conocimiento sobre la tecnología de procesos y el diseño de plantas a los productos de software de los líderes del mercado.

Contained Materials Handling solutions for Primary and Secondary Pharmaceuticals and Healthcare. With extensive experience within the generics sector, supply a wide range of technologies and equipment that improve and enhance the efficiency and performance of Oral Solid Dosage production.

The ConsiGma® DC for direct compression is the latest expansion of GEA's continuous portfolio for cost effective, compact, high yield manufacturing systems. It offers a robust and flexible manufacturing method for a wide range of products.

Continuous Processing is becoming more and more important in the pharmaceutical industry. GEA takes the lead in introducing this innovative technology with ConsiGma® - continuous high-shear granulation and drying lines.
GEA’s past fiscal year was one of significant growth and further profitability gains. In particular, the technology group substantially increased order intake, with all divisions contributing here. GEA also made progress in all Mission 30 strategic growth areas. In addition, GEA met key interim targets under its climate plan ahead of schedule. Major milestones in fiscal year 2025 were admission to the DAX index, the award of one of the largest contracts in the company’s history, and streamlining of the corporate structure.
Gracias a un nuevo centro de fabricación SmartParc, los procesadores de alimentación del Reino Unido están reduciendo sus costes de funcionamiento y sus emisiones. Con la tecnología de calefacción y refrigeración de GEA en su núcleo, este modelo de producción colaborativa demuestra cómo la innovación está acelerando las ambiciones de cero emisiones netas de la industria.
"Elaborar huevos es como elaborar cerveza". Es el tipo de comparación que te hace sonreír, y te das cuenta: De repente, algo complejo parece sencillo. Con esta película personal, ambientada en el corazón agrícola de EE.UU., exploramos la fermentación de precisión y el trabajo real que supone convertir una idea en alimentos.